论文部分内容阅读
序言氨噻肟头孢菌素(CTX)是由西德Hoec-hst公司和法国Rousell Uclaf公司共同研究成功的半合成头孢菌素(CEPs),在第10次I.C.C.及第18次I.C.A.A.C.会议上介绍它超越了以往CEPs的概念,完全作为新范畴的抗生素而登上舞台。7-氨基头孢烷酸(7ACA)的母核7位上导入a-(顺式-甲氧基亚胺基-氨基噻唑)-乙酰基,从其抗菌活性、抗菌谱,对β-内酰胺酶的稳定性,以及青霉素结合蛋白(PBP)的结合等方面来看,CTX已经达到近乎理想的物质。
INTRODUCTION Cefotaxime (CTX) is a semisynthetic cephalosporin (CEPs) successfully researched by Hoechst and the Rousell Uclaf Company in West Germany, introducing it at the 10th ICC and the 18th ICAAC meeting Beyond the concept of CEPs in the past, completely on the stage as a new category of antibiotics. A- (cis-methoxyimino-aminothiazole) -acetyl was introduced into the nucleus 7 of the 7-aminocephalosporanic acid (7ACA). From its antibacterial activity, antibacterial spectrum, CTX has achieved near-ideal properties in terms of stability, binding to penicillin-binding protein (PBP) and the like.